Elevated CA 125 levels are seen in many patients with cancer of the ovary. The percentage of positive cases increases with stage of the cancer. This assay is useful for evaluating patient’s response to ovarian cancer therapy. It also helps in predicting recurrent ovarian cancer or intraperitoneal tumor.

This assay is useful for predicting early recurrence in women treated for Carcinoma Breast. It is specially useful for serial testing in women with prior Stage II / III breast cancer who are clinically free of disease

Increased levels of CEA are found in patients with primary Colorectal carcinoma and other malignancies like Medullary thyroid carcinoma and Carcinoma of breast, GI tract, liver, lung, ovarian, pancreatic and prostate. Serial monitoring of CEA should begin prior to therapy to establish a baseline for evaluating possible recurrence. Levels generally return to normal within 1 to 4 months after removal of tumor. Smokers show a higher baseline level of CEA